Award
NIH Reporter #5K08CA258803-05
Novel targeted therapies for chronic myelomonocytic leukemia
Recipient
Dana-Farber Cancer Institute
Award Amount
$269,244.00
Ceiling
$269,244.00
Awarded
September 01, 2026
Identifier
5K08CA258803-05
This NIH-funded project aims to develop novel targeted therapies for chronic myelomonocytic leukemia by investigating genetic and pharmacologic strategies to overcome drug resistance.
Description
The project focuses on developing targeted therapies for CBL-mutant chronic myelomonocytic leukemia (CMML) using genetic and pharmacologic approaches, including CRISPR screens and drug resistance mechanisms. The research aims to identify new therapeutic targets and combination therapies to overcome drug resistance.